Skip to main content

Articles

Page 1 of 13

  3. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Roberto Crocchiolo, Clara Cesana, Debora Girgenti, Giambattista Bertani, Claudia Barba, Giuseppa Liga, Ursula Ferri, Lara Crucitti, Giovanni Grillo, Silvano Rossini and Roberto Cairoli
    Citation: Experimental Hematology & Oncology 2021 10:22
    Content type: Correction Published on:

    The original article was published in Experimental Hematology & Oncology 2021 10:14

  5. Authors: B Douglas Smith, Charles L Beach, Dalia Mahmoud, Laura Weber and Henry J Henk
    Citation: Experimental Hematology & Oncology 2014 3:19
    Content type: Erratum Published on:

    The original article was published in Experimental Hematology & Oncology 2014 3:10

  8. Vitreoretinal lymphoma (VRL) is strongly linked to central nervous system (CNS) progression with no standard treatment approaches. Commonly used strategies include repeated intraocular injections of low-dose m...

    Authors: Wenxue Guan, Liang Wang and Xiaoyan Peng
    Citation: Experimental Hematology & Oncology 2022 11:95
    Content type: Correspondence Published on:

  9. This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma c...

    Authors: Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen and Tue Wenzel Kragstrup
    Citation: Experimental Hematology & Oncology 2020 9:9
    Content type: Letter to the Editor Published on:

  10. Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously unt...

    Authors: Zhijuan Lin, Long Liu, Zhifeng Li and Bing Xu
    Citation: Experimental Hematology & Oncology 2023 12:41
    Content type: Correspondence Published on:

  11. Lung adenocarcinoma (LUAD) is a major cause of cancer-related death worldwide, and the roles of complement-related genes in it have not been thoroughly investigated yet. In the study, we aimed to systemically ...

    Authors: Lin Zhang, Yannan Yang, Weihao Lin, Fei Shao, Yibo Gao and Jie He
    Citation: Experimental Hematology & Oncology 2023 12:22
    Content type: Correspondence Published on:

  12. Authors: Ana Muntañola, Guillermo Villacampa, José Ángel Hernández-Rivas, Rosalía Alonso, Fátima Mirás, Santiago Osorio, Mónica Baile, Patricia Baltasar, Javier López Jiménez, Ines Hernandez-Rodriguez, Susana Valenciano, Ana Alfayate, Eva Gimeno, Abelardo Bárez, Ana C. Oliveira, Rosalía Riaza…
    Citation: Experimental Hematology & Oncology 2020 9:37
    Content type: Letter to the Editor Published on:

  13. Less is known about the non-mesenchymal mononuclear cell fraction of human bone marrow on functional adaptation of neuroblastoma cells. Using immunocytochemistry, we showed that bone-marrow mononuclear cell (B...

    Authors: Chareerut Phruksaniyom, Permphan Dharmasaroja and Surapol Issaragrisil
    Citation: Experimental Hematology & Oncology 2013 2:9
    Content type: Letter to the Editor Published on:

  15. Chronic lymphocytic leukemia (CLL) rarely exhibits an aggressive clinical course and its patients often have chromosomal deletions or additions. Furthermore, reciprocal translocations are barely observed in CL...

    Authors: Kayo Harada, Kazuhiko Ikeda, Hayato Matsumoto, Miki Furukawa, Hiroshi Takahashi, Hiroshi Ohkawara, Hideyoshi Noji, Kazuhiro Tasaki, Masafumi Abe, Kazuei Ogawa and Yasuchika Takeishi
    Citation: Experimental Hematology & Oncology 2012 1:28
    Content type: Case report Published on:

  16. VEXAS (vacuoles, E1 enzyme, X-linked, auto-inflammatory, somatic) syndrome is an inflammatory disorder with hematological and systemic features. A recent study demonstrated that the dermal infiltrate in neutro...

    Authors: Valentin Lacombe, Annaelle Beucher, Geoffrey Urbanski, Yannick Le Corre, Laurane Cottin, Anne Croué and Anne Bouvier
    Citation: Experimental Hematology & Oncology 2022 11:6
    Content type: Letter to the Editor Published on:

  17. Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Onco...

    Authors: Yuanhong Jiang, Siyu Wu, Rong Li, Jiazheng Yu, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Zhenqun Xu, Shijie Li and Xiaonan Chen
    Citation: Experimental Hematology & Oncology 2023 12:68
    Content type: Correspondence Published on:

  18. Breast cancer is one the most common cause of cancer death in women worldwide. We report here the first phase II study investigating a virus genetically engineered for tumor-selective replication in patients w...

    Authors: Sophie Cousin, Maud Toulmonde, Michèle Kind, Jean-Philippe Guegan, Alban Bessede, Coralie Cantarel, Carine Bellera and Antoine Italiano
    Citation: Experimental Hematology & Oncology 2022 11:104
    Content type: Correspondence Published on:

  19. From October 2017 to June 2022, we retrospectively report outcomes of R/R DLBCL patients with failure of CAR-T therapy, then receiving allo-HSCT. Among 10 patients, 5 were males and 5 females, with a median ag...

    Authors: Mengya Cong, Sicheng Ai, Liqing Kang, Mao Jin, Ying Zhu, Caixia Li, Zhengming Jin, Lei Yu, Depei Wu and Haiwen Huang
    Citation: Experimental Hematology & Oncology 2024 13:4
    Content type: Correspondence Published on:

  20. Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19 pneumonia can cause persistent lung damage and may lead to vira...

    Authors: Daiki Wada, Yasushi Nakamori, Shuhei Maruyama, Haruka Shimazu, Fukuki Saito, Kazuhisa Yoshiya and Yasuyuki Kuwagata
    Citation: Experimental Hematology & Oncology 2022 11:53
    Content type: Correspondence Published on:

  21. Common variable immunodeficiency (CVID) was a kind of primary immunodeficiency disorders with heterogeneous phenotype and genotype. Lipopolysaccharide-responsive and beige-like anchor (LRBA) mutation was ident...

    Authors: Yanling Ren, Feng Xiao, Fei Cheng, Xin Huang, Jianhu Li, Xiaogang Wang, Wei Lang, Xinping Zhou, Jianping Lan and Hongyan Tong
    Citation: Experimental Hematology & Oncology 2021 10:38
    Content type: Letter to the Editor Published on:

  22. Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1...

    Authors: Sakshi Jasra, Mohammed Kazemi, Nishi Shah, Jiahao Chen, Karen Fehn, Yanhua Wang, Ioannis Mantzaris, Noah Kornblum, Alejandro Sica, LizaMarie Bachier, Mendel Goldfinger, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Aditi Shastri and Amit Verma
    Citation: Experimental Hematology & Oncology 2021 10:1
    Content type: Letter to the Editor Published on:

  23. Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of a...

    Authors: Jingyi Yang, Hao Guo, Lu Han, Yongping Song and Keshu Zhou
    Citation: Experimental Hematology & Oncology 2024 13:25
    Content type: Correspondence Published on:

  25. An elevated platelet count has been associated with an increased incidence of cancer and poor survival for many cancer types. In this study, platelet levels were captured among cancer patients in the 2 years p...

    Authors: Vasily Giannakeas
    Citation: Experimental Hematology & Oncology 2022 11:16
    Content type: Letter to the Editor Published on:

  26. The development of programmed cell death-1 inhibitor (PD-1) has shed light on the treatment of tumors with deficiencies in DNA mismatch repair system or microsatellite instability (dMMR/MSI). However, predicti...

    Authors: Qiao-Xuan Wang, Chun-Hua Qu, Yuan-Hong Gao, Pei-Rong Ding, Jing-Ping Yun, Dan Xie and Mu-Yan Cai
    Citation: Experimental Hematology & Oncology 2021 10:2
    Content type: Letter to the Editor Published on:

  28. Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two consecutively negative SARS-CoV-2 viral RNA test ( interv...

    Authors: Changqian Bao, Xiandong Tao, Wei Cui, Yuanyuan Hao, Shuaike Zheng, Bin Yi, Tiewen Pan, Ken H. Young and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2021 10:5
    Content type: Letter to the Editor Published on:

  29. Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a mul...

    Authors: Emma Rabinovich, Kith Pradhan, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Ioannis Mantzaris, Noah Kornblum, Aditi Shastri, Kira Gritsman, Mendel Goldfinger, Amit Verma and Ira Braunschweig
    Citation: Experimental Hematology & Oncology 2021 10:55
    Content type: Letter to the Editor Published on:

  30. Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatmen...

    Authors: Kaiqi Liu, Yan Li, Shaowei Qiu, Chunlin Zhou, Shuning Wei, Dong Lin, Guangji Zhang, Hui Wei, Ying Wang, Bingcheng Liu, Xiaoyuan Gong, Qiuyun Fang, Yang Song, Huijun Wang, Chengwen Li, Qinghua Li…
    Citation: Experimental Hematology & Oncology 2021 10:46
    Content type: Letter to the Editor Published on:

  31. Tirabrutinib (ONO/GS-4059; Ono Pharmaceutical) is a newly developed drug that selectively and irreversibly inhibits Bruton’s tyrosine kinase (BTK) and has been approved in Japan for treating relapsed/refractor...

    Authors: Yoshiko Okita, Rieko Kano-Fujiwara, Shin-Ichi Nakatsuka, Keiichiro Honma and Manabu Kinoshita
    Citation: Experimental Hematology & Oncology 2021 10:29
    Content type: Letter to the Editor Published on:

  32. Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of va...

    Authors: Rong Ma, Jia-Lin Wang and Yan-Yang Wang
    Citation: Experimental Hematology & Oncology 2022 11:78
    Content type: Correspondence Published on:

  33. Disease relapse after allogeneic stem cell transplantation is a major cause of treatment-related morbidity and mortality in patients with myeloproliferative neoplasms (MPNs). The cellular and molecular mechani...

    Authors: Haotian Zhang, Melissa Castiglione, Lei Zheng and Huichun Zhan
    Citation: Experimental Hematology & Oncology 2021 10:47
    Content type: Letter to the Editor Published on:

  34. Acute promyelocytic leukemia (APL) is highly aggressive and is frequently associated with disseminated intravascular coagulation and high early death rates. Although all-trans retinoic acid (RA) induces comple...

    Authors: Xubo Gong, Piaoping Kong, Teng Yu, Xibin Xiao, Lin Wang, Yiwen Sang, Xiang Li, Bin Zhang, Zhihua Tao and Weiwei Liu
    Citation: Experimental Hematology & Oncology 2022 11:103
    Content type: Correspondence Published on:

  35. Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells. We synthesized four single VHH-...

    Authors: Quan Ren, Yingling Zu, Hongchang Su, Qiumei Lu, Bin Xiang, Yanping Luo, Jishuai Zhang and Yongping Song
    Citation: Experimental Hematology & Oncology 2023 12:98
    Content type: Correspondence Published on:

  36. Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intoleran...

    Authors: Klára Gadó, András Matolcsy, Judit Csomor, Dóra Kicsi, Csaba Bödör and Gyula Domján
    Citation: Experimental Hematology & Oncology 2012 1:17
    Content type: Letter to the Editor Published on:

  37. The aim of the present study was to evaluate the circulating T regulatory cells (Tregs) in patients undergoing extracorporeal photopheresis (ECP) for the prevention of chronic graft-versus-host disease (GvHD) ...

    Authors: Roberto Crocchiolo, Clara Cesana, Debora Girgenti, Giambattista Bertani, Claudia Barba, Giuseppa Liga, Ursula Ferri, Lara Crucitti, Giovanni Grillo, Silvano Rossini and Roberto Cairoli
    Citation: Experimental Hematology & Oncology 2021 10:14
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in Experimental Hematology & Oncology 2021 10:22

  38. Hetrombopag, a small molecular thrombopoietin-receptor agonist, has shown encouraging efficiency in immunosuppressive therapy refractory or relapsed severe aplastic anaemia. To investigate the response rate of...

    Authors: Wenrui Yang, Xin Zhao, Xu Liu, Youzhen Xiong, Huihui Fan, Li Zhang, Jianping Li, Lei Ye, Kang Zhou, Yuan Li, Yang Yang, Guangxin Peng, Liping Jing and Fengkui Zhang
    Citation: Experimental Hematology & Oncology 2023 12:16
    Content type: Correspondence Published on:

  39. Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) is a very rare lymphoma with an aggressive clinical course and a dismal outcome. The prognosis is linked to a pronounced resistance to chemotherapy and ...

    Authors: Sophie Voruz, Laurence de Leval and Anne Cairoli
    Citation: Experimental Hematology & Oncology 2021 10:32
    Content type: Letter to the Editor Published on:

  40. Interferon regulatory factor 4 (IRF4) is involved in the pathogenesis of various hematologic malignancies. Its expression has been related to the negative regulation of myeloid-derived suppressor cells (MDSCs) an...

    Authors: Cosimo Cumbo, Francesco Tarantini, Luisa Anelli, Antonella Zagaria, Immacolata Redavid, Crescenzio Francesco Minervini, Nicoletta Coccaro, Giuseppina Tota, Alessandra Ricco, Elisa Parciante, Maria Rosa Conserva, Giorgina Specchia, Pellegrino Musto and Francesco Albano
    Citation: Experimental Hematology & Oncology 2021 10:58
    Content type: Letter to the Editor Published on:

  41. In this study, we established a novel immunologic gene prognostic index (IGPI) to predict metastasis and provided new insights into tumor immune microenvironment (TIME) for PCa patients receiving radical radio...

    Authors: Dechao Feng, Weizhen Zhu, Xu Shi, Zhihong Wang, Wuran Wei, Qiang Wei, Lu Yang and Ping Han
    Citation: Experimental Hematology & Oncology 2023 12:8
    Content type: Correspondence Published on:

  43. Taxanes plus carboplatin (TP) regimen may be an acceptable alternative adjuvant chemotherapy strategy in patients with triple-negative breast cancer (TNBC); however, the difference with the anthracycline-based...

    Authors: Fangchao Zheng, Tong Wei, Xue Wang, Feng Du, Jian Yue and Peng Yuan
    Citation: Experimental Hematology & Oncology 2022 11:65
    Content type: Correspondence Published on:

  44. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies. However, there is no data on the safety and efficacy of CAR T-cell therapy in patient...

    Authors: Bradley D. Hunter, Daanish Hoda, Andy Nguyen, Launce Gouw, Bryan Huber, Ryan R. Jensen, Justine Preedit, Andrew Evens, Esther Huang, Jiyeon Park and Dennis L. Cooper
    Citation: Experimental Hematology & Oncology 2022 11:10
    Content type: Letter to the Editor Published on:

  45. Erythrocytosis is a clinical condition characterized by increased red cell mass, hemoglobin, and hematocrit values. A significant fraction of patients is described as having idiopathic erythrocytosis. We have ...

    Authors: Antonella Zagaria, Francesco Tarantini, Paola Orsini, Luisa Anelli, Cosimo Cumbo, Nicoletta Coccaro, Giuseppina Tota, Crescenzio Francesco Minervini, Elisa Parciante, Maria Rosa Conserva, Immacolata Redavid, Alessandra Ricco, Immacolata Attolico, Giorgina Specchia, Pellegrino Musto and Francesco Albano
    Citation: Experimental Hematology & Oncology 2022 11:47
    Content type: Correspondence Published on:

  46. Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the...

    Authors: Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li and Lijuan Chen
    Citation: Experimental Hematology & Oncology 2021 10:16
    Content type: Letter to the Editor Published on:

  47. We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later e...

    Authors: Yulei Wang, Li-Chun Lu, Yinghui Guan, Ming-Chih Ho, Shan Lu, Jessica Spahn and Chih-Hung Hsu
    Citation: Experimental Hematology & Oncology 2021 10:45
    Content type: Letter to the Editor Published on:

  48. CAR T cell therapy has been successfully used in the treatment of hematological malignancies, and the strategy that deletion of inhibitory receptor on the CAR T cell surface, such as PD-1, greatly enhance the ...

    Authors: Ming Liu, Linlin Zhang, Mingtian Zhong, Yihao Long, Wenhui Yang, Ting Liu, Xingxu Huang and Xiaodong Ma
    Citation: Experimental Hematology & Oncology 2023 12:88
    Content type: Correspondence Published on:

  49. Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing nu...

    Authors: Jiangxue Hou, Yufu Li and Quande Lin
    Citation: Experimental Hematology & Oncology 2023 12:74
    Content type: Correspondence Published on:

    The Correction to this article has been published in Experimental Hematology & Oncology 2023 12:86

  50. The in vitro erythrocyte differentiation model remains a strong, clinically relevant tool to model erythroid development in normal and disease related hematopoiesis. This model also has application to developi...

    Authors: Matthew Cannon, Hannah Phillips, Sidney Smith, Shaneice Mitchell, Kristina Landes, Payal Desai, John Byrd and Rosa Lapalombella
    Citation: Experimental Hematology & Oncology 2021 10:50
    Content type: Letter to the Editor Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    11.4 - 2-year Impact Factor
    7.3 - 5-year Impact Factor
    1.609 - SNIP (Source Normalized Impact per Paper)
    1.908 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage
    696,150 downloads
    375 Altmetric mentions

On the blog

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us